Measurable Residual Disease Before Reduced-Intensity Allogeneic Transplantation in Patients With Myeloid Malignancy. Gui G, Dillon LW, Hourigan CS. J Clin Oncol 2021;39:2413-2415.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Gui G, Dillon LW, Hourigan CS. Measurable Residual Disease Before Reduced-Intensity Allogeneic Transplantation in Patients With Myeloid Malignancy. J Clin Oncol 2021;39:2413-2415.
PMID: 33950704